Abstract | PURPOSE: We have previously shown that PTEN loss confers trastuzumab resistance in ErbB2-overexpressing breast cancer using cell culture, xenograft models, and patient samples. This is a critical clinical problem because trastuzumab is used in a variety of therapeutic regimens, and at the current time, there are no established clinical strategies to overcome trastuzumab resistance. Here, we did preclinical studies on the efficacy of clinically applicable inhibitors of the Akt/ mammalian target of rapamycin (mTOR) pathway to restore trastuzumab sensitivity to PTEN-deficient cells. EXPERIMENTAL DESIGN: Cell culture and xenograft models were used to test a panel of clinically applicable, small-molecule inhibitors of the Akt/mTOR signal transduction pathway, a critical pathway downstream of ErbB2, and identify compounds with the ability to restore trastuzumab sensitivity to PTEN-deficient cells. RESULTS: CONCLUSIONS:
|
Authors | Chien-Hsing Lu, Shannon L Wyszomierski, Ling-Ming Tseng, Meng-Hong Sun, Keng-Hsueh Lan, Christopher L Neal, Gordon B Mills, Gabriel N Hortobagyi, Francisco J Esteva, Dihua Yu |
Journal | Clinical cancer research : an official journal of the American Association for Cancer Research
(Clin Cancer Res)
Vol. 13
Issue 19
Pg. 5883-8
(Oct 01 2007)
ISSN: 1078-0432 [Print] United States |
PMID | 17908983
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, Non-P.H.S.)
|
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Ribonucleosides
- triciribine
- Everolimus
- PTEN Phosphohydrolase
- PTEN protein, human
- Bromodeoxyuridine
- Trastuzumab
- Sirolimus
|
Topics |
- Animals
- Antibodies, Monoclonal
(pharmacology)
- Antibodies, Monoclonal, Humanized
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Bromodeoxyuridine
(pharmacology)
- Cell Line, Tumor
- Drug Resistance, Neoplasm
- Drug Screening Assays, Antitumor
(methods)
- Everolimus
- Female
- Humans
- Mice
- Mice, SCID
- Neoplasm Transplantation
- Neoplasms
(drug therapy)
- PTEN Phosphohydrolase
(deficiency, genetics)
- Ribonucleosides
(administration & dosage)
- Sirolimus
(administration & dosage, analogs & derivatives)
- Trastuzumab
|